Access to Medicine

Timely access to new medicines saves lives, improves health outcomes, helps reduce healthcare costs, contributes to economic productivity, and makes Canada a more attractive destination for future investment and innovation.

The Problem

Two years is too long.

Canadian patients wait two years for access to approved new medicines through public drug plans. Patients in most peer countries get access to approved new medicines over one year sooner than Canadians.

The Impact

Canadians, our health systems & our economy pay the price.

Delays in patient access to medicines lead to:

  • Fewer life sciences investments, clinical trials, and drug launches;
  • Increased strain on health systems and health human resources; and
  • A missed opportunity to increase quality of life and improve health outcomes for Canadians.

The Opportunity

Faster access for all.

There are two immediate actions provincial and territorial governments can take to get Canadians much faster access to new medicines.

  1. Eliminate the 119-day delay between CADTH and pCPA.
  2. Commit to listing new medicines on public drug plans within 30 days of a completed pCPA negotiation.

Get Involved

Join the conversation.

Become a catalyst for change by spreading the word about Access to Medicine in Canada – follow IMC on social media, share our infographics, and inspire others to join the conversation for a healthier future.

Download the infographics above and post on your social channels.

Newsroom

Breaking down and analyzing current events in the healthcare industry for our members, policy influencers and the Canadian public.

About

Our member companies, which range from early-stage startups to established organizations, are revolutionizing healthcare through the discovery and development of new […]

resources

Discover. Learn.
Understand.

Informative content to keep you up to date on the most pressing issues facing our industry.